.png)
Health check programmes across Singapore, Hong Kong and Malaysia have invested heavily in clinical infrastructure. Risk calculators run faster, digital records are more complete, and the clinical case for early cardiovascular risk identification is settled. Yet cardiovascular disease still accounts for nearly 40% of all deaths in the Western Pacific,[1] and crude cardiovascular mortality across Asia is projected to rise by more than 90% by 2050 despite improvements in age-standardised rates.[2]
The burden is not growing because health checks are unavailable. It's growing because of two failures that sit between the risk score and the patient's next step: applying the wrong equation to the wrong population, and doing nothing structured with the result once it's produced.
The Framingham Risk Score has shaped preventive cardiology for decades. It is well-validated, widely used, and embedded in more health check platforms than any other model. It is also calibrated on a New England cohort enrolled from the 1940s onward — and in the multi-ethnic populations of Singapore, Hong Kong and Malaysia, it can be systematically wrong.
The error is not random, and it cannot be corrected with a single adjustment. Research from the Asia Pacific Cohort Studies Collaboration found that Framingham overestimated cardiovascular risk in Chinese men by an average of 276% and in Chinese women by 102%.[3] In South Asian populations the direction reverses — the same equations tend to underestimate risk. One equation applied to a multi-ethnic cohort does not produce a single calibration error. It produces several, running in different directions at the same time.
This is precisely why each market in the region has moved to population-matched scoring.
Singapore mandates the Singapore-modified Framingham Risk Score 2023 (SG-FRS-2023), recalibrated on multi-ethnic cohort data by the Saw Swee Hock School of Public Health and the Ministry of Health.[4] It carries separate risk tables for Chinese, Malay and Indian patients — because at an identical risk-factor profile, a Malay and a Chinese man can sit more than 26 percentage points apart in 10-year coronary artery disease risk. A single equation flattens that difference entirely.
Malaysia uses the Framingham General Cardiovascular Disease Risk Score (FRS-CVD), validated in the multi-ethnic Malaysian population and embedded in the 2017 national clinical practice guidelines.[5] Independent validation has confirmed it retains calibration gaps — consistent with the broader evidence that no imported Western equation transfers cleanly to Asian populations without local adjustment.[6]
Hong Kong's 2016 professional consensus recommends structured risk assessment — the American Pooled Cohort Equations or the European SCORE system — for every adult aged 40 or older with at least one cardiovascular risk factor.[7] Researchers have gone further: locally derived models P-CARDIAC and 1°P-CARDIAC, built and validated on Hospital Authority cohorts, both outperformed the Pooled Cohort Equations, China-PAR and Framingham head-to-head in Hong Kong data — consistent evidence that population-tuned models read local risk more accurately than borrowed ones.[8][9]
For operators running health checks that serve mixed or expatriate populations, the implication is direct. A Caucasian or American member of a mobile workforce is most accurately assessed using a US-derived equation. An Asian colleague at the same screening event warrants an ethnicity-appropriate, locally validated score. Applying one default to an entire cohort does not simplify the process — it introduces layered, systematic misclassification across different ethnic groups simultaneously.
Even with the right equation applied, a risk number without a defined next step produces no clinical value. Guidelines already map the path. In Singapore, a 10-year CAD risk of ≥10% is the threshold at which a moderate-intensity statin is indicated for most patients. In Malaysia, an FRS-CVD score ≥20% places a patient in the high-risk category with a clear pharmacological and lifestyle management mandate.
For patients in the intermediate range — where the decision to treat is genuinely uncertain — coronary artery calcium (CAC) scoring provides the most evidence-backed reclassification tool available. The Multi-Ethnic Study of Atherosclerosis found that a CAC score of zero was the strongest negative risk marker across all markers tested, supporting safe deferral of statin therapy in appropriate patients.[10] A CAC ≥100 substantially upgrades risk, justifying earlier and more aggressive intervention.
The operational failure is well-documented. A study of more than 5,000 outpatient records found that clinicians failed to follow up, or document follow-up on, clinically significant abnormal results in approximately 1 in every 14 cases — with variation across practices reaching as high as 1 in 4.[11] A health check that identifies elevated risk but cannot confirm the finding reached an appropriate next step has not completed its job.
The gap most health check programmes do not measure is not in the risk score — it's in what happens between the result being generated and a clinical action being taken. The number is documented. The follow-up is not.
DARA® builds in a portfolio of clinically validated risk calculators covering cardiovascular disease, diabetes, hypertension, chronic kidney disease and MAFLD, each using the prediction horizon appropriate to its disease. It selects the population-appropriate CVD score based on the patient's ethnicity and clinical profile, interprets results against guideline thresholds, prioritises findings by risk level, and tracks referrals through to completion. Every elevated result has a documented pathway — not just a number on a report.
The calculation is the first step. What the clinician needs is interpretation, prioritisation, and confirmation that the loop has closed.
For Medical Directors and health check operators, there is a commercial case that follows directly from the clinical one.
A risk score that triggers the appropriate follow-up — statin initiation, a CAC referral, a specialist appointment, a repeat screen at an adjusted interval — turns a single health check encounter into a clinical relationship. The operators who sustain and grow their programmes are typically the ones whose results lead somewhere. Appropriate action builds the trust that brings patients back, justifies premium programme positioning, and drives referral volume through the services that follow.
Acting on the right risk, for the right patient, at the right time is not a marketing position. It is what a screening programme is for — and it is where durable value in preventive health care is made.
To see how DARA® selects population-appropriate risk scores and closes the loop on follow-up across your health check programme, book a 20-minute walkthrough.
References used in this post
